# Synphatec

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/synphatec

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.synphatec.com/
- Latest round: Series A (Sep 28, 2026)
- Investors on record: 6

## About

Based in Shanghai, China and founded in 2021, Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd., trading as Synphatec, focuses on research and development of novel treatments for central nervous system disorders. In September 2026, Synphatec raised over USD 50 million in Series A funding led by Decheng Capital, with participation from Huatai Zijin Investment, China Merchants Venture Investment Management, 5Y Capital, Shunwei Capital and Qianju Capital.

The company focuses on advancing its pipeline of preclinical and early-stage clinical programs targeting psychiatric and neurodegenerative diseases such as depression and Alzheimer's disease.

The company's revenue is generated by providing novel treatments for central nervous system disorders.

The company will use the funding to advance the clinical development of core pipeline assets SP-101 and SP-201, optimize the i-NaS and SynX technology platforms, and further expand the innovative pipeline to address significant unmet clinical needs.

## Funding rounds

- Series A, Sep 28, 2026 — 5Y Capital, Decheng Capital, Shunwei Capital, Huatai Zijin Investment, China Merchants Venture Investment Management, Qianju Capital

## Investors

- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series A
- Decheng Capital (https://capitalatlas.ai/funds/decheng-capital) — Series A
- Shunwei Capital (https://capitalatlas.ai/funds/shunwei-capital) — Series A
- Huatai Zijin Investment (https://capitalatlas.ai/funds/huatai-zijin-investment) — Series A
- China Merchants Venture Investment Management (https://capitalatlas.ai/funds/china-merchants-venture-investment-management) — Series A
- Qianju Capital — Series A